Qiagen

Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday MarketBeat

Qiagen N.V. (NYSE:QGEN) Receives Average Rating of "Hold" from Analysts MarketBeat

Is Qiagen NV (QGEN) a Bargain After 10.7% Drop? GF Value Says Un GuruFocus

Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1 Yahoo Finance

Qiagen N.V. 2026 Q1 - Results - Earnings Call Presentation (NYSE:QGEN) 2026-04-28 Seeking Alpha

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per s

A drop in immigration testing demand forces QIAGEN to reset 2026 goals Stock Titan

Qiagen N.V. (QGEN) Stock Analysis: Exploring A 40% Potential Upside For Investors DirectorsTalk Interviews

Is Qiagen’s (QGEN) New Infection and Oncology Tools Quietly Rewiring Its Diagnostics Moat? simplywall.st

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 i

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plu

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended De

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and aut

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that c

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, a

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability tar